In a paper published in the premier open-access medical journal PloS Medicine this month, Mukesh Harisinghani and Ralph Weissleder describe a technique that could begin to make the staging of cancer both more accurate and less invasive. Correct staging of cancers is one of the most important parts of the work up of patients for both prediction of outcome and determination of the most appropriate treatment. But at the moment many staging techniques either require surgery or are not sufficiently accurate.

The authors used extremely small magnetic particles (called nanoparticles) that homed to lymph nodes, and then tracked the nodes using MRI. In a study in 70 patients with a range of different cancers—36 that they developed the technique on and 34 that they tested the results on—the authors were able to see different patterns for normal and malignant nodes. It was then possible to design a computer program that could recognize metastases. And then the program was able to produce a 3-D reconstruction of the lymph nodes which could possibly be used by oncologists and surgeons to provide optimal treatment. “This method of cancer staging provides unprecedented accuracy and will spare unnecessary surgery” says Dr. Weissleder.

Citation: Harisinghani M, Weissleder R (2004) Sensitive, noninvasive detection of lymph node metastases. PLoS Med 1 (3): e66.

The published article is at:
http://www.plosmedicine.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0010066

CONTACT:
Ralph Weissleder
Harvard Medical School
Massachusetts General Hospital
Center for Molecular Imaging Research
149 13th St. Room 5403
Charlestown, MA USA 02129
+1-617-726-8226
+1-617-726-5708 (fax)
weissleder@helix.mgh.harvard.edu

3-D image of lymph node after automated analysis.
Courtesy of Ralph Weissleder.

If you have a relative with cancer, probably one of the most pressing questions is what your chances are of getting it yourself. In a paper published in PloS Medicine, the premier medical journal freely available online, Laufey Amundadottir and colleagues from deCODE genetics (a company that is using genetics to develop new drug treatments) and Iceland’s National-University Hospital go some way toward answering that question. They analyzed comprehensive data on the most common forms of cancer from Iceland’s National Cancer Registry in the context of deCODE’s nationwide genealogy database. This enabled Dr. Amundadottir and her team to establish how often cancers occurred in first through fifth degree relatives of some 32,000 cancer patients over the past 50 years.

For 16 of the 27 cancers studied, the results indicate that relatives of patients are at a significantly higher risk of developing cancer than are members of the population at large. For some cancers this increased risk even extended out to distant (i.e. 3rd to 5th degree) relatives. Cancers in certain sites also showed a familial association with other cancers—for example relatives of individuals with stomach, colon, rectal, or endometrial cancer were more likely to develop one of these cancers, although not necessarily in the same site as did their relative. Three cancers—stomach, lung and colon cancer—were also seen more frequently in the mates of patients, confirming that shared lifestyle or environmental factors such as smoking, diet or exercise habits also contribute substantially to the increased risk.

The seven cancers with the highest increased familial occurrence both in close and distant relatives were breast, prostate, stomach, lung, colon, kidney and bladder cancers. However, even for these cancers the increased relative risk for first-degree relatives was generally less than twice that for the population at large, and this risk diminished significantly for second-degree and more distant relatives.

“By utilizing a population approach, we have been able to draw a portrait of cancer risk as a public health problem over the span of many decades. Our findings indicate that genetic factors contribute to the risk of specific cancers, but also that certain types of cancer can be looked upon collectively as broad, complex phenotypes. The next step in this work is to isolate the key genes contributing to the common forms of the disease and to use this information to develop better medicine. At the same time it is crucial to emphasize that lifestyle and environmental factors play a very significant role in the development of cancer and are things we may all be able to do something about today,” said Kari Stefansson, CEO of deCODE and senior author on the study.

Citation: Amundadottir L, Thorvaldsson S, Gudbjartsson D, Sulem P, Kristjansson, et al. (2004) Cancer as a complex phenotype: Pattern of cancer distribution within and beyond the nuclear family. PLoS Med 1 (3): e65.

The published article is accessible at:
http://www.plosmedicine.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0010065

CONTACT:
Laufey Amundadottir
deCODE genetics
Cancer genetics
Sturlugata 8
Reykjavik, Iceland 101
+354-664-1822
+354-570-1903 (fax)
laufey@decode.is

About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org

About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere—to read, download, redistribute, include in databases, and otherwise use—subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

Reference URL
http://www.plosmedicine.org